FDA Rejects Silenor Insomnia Treatment
The US Food and Drug Administration (FDA) issued a Complete Response Letter to Somaxon Pharmaceuticals, San Diego, for the company’s New Drug Application (NDA) for its insomnia drug Silenor® (doxepin). After review the FDA determine
Read More